US equities |
MU $1,088.00 ▲+4.06% NVDA $237.47 ▼-0.74% SNDK $1,692.42 ▲+1.92% SPCX $167.60 ▼-2.51% AMD $645.86 ▼-0.55% AAPL $336.67 ▲+0.91% TSLA $377.81 ▼-0.75% META $721.31 ▼-2.38%
FinancialContent

Latest News about Aduhelm

Recent news which mentions Aduhelm

Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock
Tickers BIIB ESALY
Tags Aduhelm Analyst Color lecanemab
From Benzinga
Researchers Investigate New Treatment Pathways For Alzheimer's After Commercial Failure Of Biogen's Aduhelm
Tickers BIIB
Tags BIIB Alzheimer's disease Market News
From Benzinga
Biogen's Alzheimer's Drug Aduhelm Medicare Coverage Restricted To Just Clinical Trials, CMS Finalizes
Tickers BIIB
Tags General Government Biotech
From Benzinga
Aduhelm's 'Blockbuster Potential' Is Underappreciated, Says Biogen Analyst
Tickers BIIB
Tags Market News BIIB Alzheimer's disease
From Benzinga
After Aduhelm Win, Biogen Touts Encouraging Data From Second Alzheimer's Candidate
Tickers BIIB IONS
Tags General Biotech Benzinga
From Benzinga
Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients
Tickers BIIB ESALF ESALY
Tags Biotech Benzinga ESALY
From Benzinga
Biogen Shares Are Trading Lower As Cleveland Clinic, Mount Sinai Decline To Aduhelm Administration
Tickers BIIB
Tags General Benzinga Aduhelm
From Benzinga
FDA Requests Probe Into Staff Interactions With Biogen Ahead Of Aduhelm Approval
Tickers BIIB
Tags FDA BIIB News
From Benzinga
FDA Narrows Label To Recommend Use Of Biogen's Aduhelm In Mild Alzheimer's Patients
Tickers BIIB ESALY
Tags News Market News BIIB
From Benzinga